Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 11:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–36 of 12 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HRD Cancer Clear all
Terminated Phase 2 Interventional Results available

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

NCT03712930
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC), Homologous Recombination Deficiency (HRD)
Interventions
Pamiparib
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Athens, Georgia • The Bronx, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Jun 25, 2026, 11:07 AM EDT
Not listed Phase 2 Interventional

Niraparib and Dostarlimab in HRD Solid Tumors

NCT04983745
View directory record Official record
Conditions
Homologous Recombination Deficient Solid Tumors
Interventions
Combination drug
Drug
Lead sponsor
West Cancer Center
Other
Eligibility
Up to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Jun 25, 2026, 11:07 AM EDT
Recruiting Phase 1 Interventional

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

NCT06177171
View directory record Official record
Conditions
BRCA1 Mutation, BRCA2 Mutation, BRCA Mutation, PALB2 Gene Mutation, Checkpoint Kinase 2 Gene Mutation, ATM Gene Mutation
Interventions
Olaparib, ASTX727
Drug
Lead sponsor
Varun Monga, MBBS
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 25, 2026, 11:07 AM EDT
Recruiting Phase 2 Interventional

Olaparib in Patients With HRD Malignant Mesothelioma

NCT04515836
View directory record Official record
Conditions
Mesothelioma, Homologous Recombination Deficiency
Interventions
Olaparib
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Jun 25, 2026, 11:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

NCT01482715
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Advanced Solid Tumor With Evidence of Germline or Somatic BRCA
Interventions
Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
6
States / cities
San Francisco, California • Sarasota, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Jun 25, 2026, 11:07 AM EDT
Recruiting Phase 3 Interventional

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

NCT06580314
View directory record Official record
Conditions
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Carcinoma, Ovarian High Grade Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions
Bevacizumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib
Biological · Procedure · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
658
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 447 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jun 25, 2026, 11:07 AM EDT
Completed Phase 3 Interventional Results available

A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

NCT02975934
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
Rucaparib, Abiraterone acetate or Enzalutamide or Docetaxel
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Male only
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Jun 25, 2026, 11:07 AM EDT
Completed Phase 2 Interventional Results available

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

NCT01982448
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Cisplatin, Paclitaxel
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
20
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Baltimore, Maryland + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Jun 25, 2026, 11:07 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

NCT04826341
View directory record Official record
Conditions
HRD Cancer, SCLC, Advanced Solid Tumors
Interventions
Berzosertib, Sacituzumab Govitecan
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 25, 2026, 11:07 AM EDT
Terminated Phase 1Phase 2 Interventional

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

NCT06065059
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer, BRCA1 Mutation, BRCA-Mutated Ovarian Carcinoma, BRCA-Associated Breast Carcinoma, HRD Positive Advanced Ovarian Cancer
Interventions
TNG348, Olaparib
Drug
Lead sponsor
Tango Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Denver, Colorado • Orange City, Florida • Sarasota, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Jun 25, 2026, 11:07 AM EDT
Terminated Phase 2 Interventional Results available

A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)

NCT06964165
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Niraparib, Carboplatin, Paclitaxel
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
San Francisco, California • Miami, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Jun 25, 2026, 11:07 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

NCT03875313
View directory record Official record
Conditions
Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer, CRC, RCC, ccRCC
Interventions
CB-839, Talazoparib
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Jun 25, 2026, 11:07 AM EDT